Oral Azacitidine Combination Met Phase 3 Trial Goals
The drug regimen ASTX030 met its primary pharmacokinetic endpoint in a clinical trial for blood disorders.
Updated on Oct. 1, 2026 in Cancer
Live Poll
Do you believe oral treatment options are generally preferable to injectable therapies for chronic health conditions?
Taiho Oncology announced that its oral combination of azacitidine and cedazuridine, known as ASTX030, successfully met its primary pharmacokinetic endpoint in a phase 3 study. The regimen is intended for adults with myelodysplastic syndromes or chronic myelomonocytic leukemia.
Why it matters
The combination of these two drugs allows azacitidine to remain active in the body without degradation. If approved, the oral treatment could offer an alternative to traditional parenteral administration for patients with specific blood disorders.
The trial measured the total cycle azacitidine area under the curve from 0 to 24 hours in 88 adult patients. Participants were required to swallow the medication within 10 minutes and adhere to 4 hours of fasting.
The players
Taiho Oncology
This pharmaceutical company is responsible for the clinical development of ASTX030 and intends to seek FDA approval for the oral regimen.
The details
The study compared the oral regimen to subcutaneous administration in patients with an ECOG performance status of 0 or 1. Researchers noted that the safety profile observed during the crossover study remained consistent with parenteral azacitidine.
Timeline
Topline results from the phase 3 trial were released on September 30, 2026.
The article was published on October 1, 2026.
The Big Picture
This development follows a trend of pharmaceutical efforts to transition injectable chemotherapies to oral delivery formats to improve patient experience. The success in this study updates the data profile previously established by the AZTOUND clinical trial.
Patients currently managing myelodysplastic syndromes or chronic myelomonocytic leukemia may eventually have an oral treatment alternative to injections. The safety profile observed so far is consistent with the current parenteral version of the drug.
The takeaway
This oral regimen seeks to simplify administration for patients who currently rely on parenteral treatments. The trial results mark a significant step toward a potential FDA submission for the combination drug.
Further reading
Learn more about the latest research and standard of care in Cancer studies.
More information
Read the comprehensive AZTOUND clinical trial details on the federal registry.
Source note: This article includes information reported by OncLive.
Live Poll
Do you believe oral treatment options are generally preferable to injectable therapies for chronic health conditions?
